Autoimmune Gastrointestinal Dysmotility Market Analysis 2025 – Insights for Long-Term Investment & Planning

June 16, 2025 09:35 PM AEST | By EIN Presswire
 Autoimmune Gastrointestinal Dysmotility Market Analysis 2025 – Insights for Long-Term Investment & Planning
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- What Does The Data On The Autoimmune Gastrointestinal Dysmotility Market Size Indicate?
The Autoimmune Gastrointestinal Dysmotility Global Market is expected to surge from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate CAGR of 6.0%. This strong growth trend is accredited to increasing unawareness of rare diseases, escalating frequency of misdiagnosis with other gastrointestinal GI disorders, the rise in underdeveloped diagnostic practices, and delays in research progress in the historic period.

What Does The Future Hold For The Autoimmune Gastrointestinal Dysmotility Market?
Over the next few years, the autoimmune gastrointestinal dysmotility market is poised to grow steadily to $2.30 billion in 2029, at a CAGR of 5.9%. This substantial growth in the forecast period can be attributed to increasing autoimmune disease prevalences, advances in diagnostic techniques, increased healthcare expenditure, the establishment of rare disease registries, and enhanced clinician education. Key transformative factors, including advancements in diagnostic technology, innovations in immunotherapy, development of neurogastroenterology research, engaged research in motility modulators, and personalized treatment approaches, have contributed to the forecast period trends.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp

What Factors Are Driving The Growth Of Autoimmune Gastrointestinal Dysmotility Market?
Autoimmune diseases, where the body's immune system erroneously attacks its healthy cells, tissues, or organs, are seeing a surge in occurrence. This unfortunate mishap in the immune system can primarily be pinned on a combination of genetic susceptibility and environmental triggers, which disrupt immune system regulation and increase the likelihood of the body attacking its own tissues. Therefore, increasing prevalence of autoimmune disorders is a significant growth driver for the autoimmune gastrointestinal dysmotility market, going forward.

Additionally, an upward trajectory in the focus on personalized medicine is anticipated to propel the market surge. The birth of personalized medicine comes hand-in-hand with advancements in genomics, enabling precise identification of genetic variations and subsequently, individuals' tailored treatments. These therapies enhance treatment efficacy, minimize side effects, and present more targeted solutions for managing complex gastrointestinal disorders.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/autoimmune-gastrointestinal-dysmotility-global-market-report

Who Are The Key Players In The Autoimmune Gastrointestinal Dysmotility Market?
The autoimmune gastrointestinal dysmotility market landscape is graced by major companies, including AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, and many more. These companies have been focusing on strategic partnerships to offer advanced digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions - leading to improved symptom management, access to care, and cost efficiency.

How Is The Autoimmune Gastrointestinal Dysmotility Market Segmented?
1 By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2 By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3 By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction Cipo, Functional Dyspepsia, Irritable Bowel Syndrome Ibs, Celiac Disease
4 By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5 By End User: Hospitals, Clinics, Home Care Settings, Research Institutions

What Are The Regional Insights Of The Autoimmune Gastrointestinal Dysmotility Market?
In 2024, North America was the largest region in the autoimmune gastrointestinal dysmotility market. The markets across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa have also been analyzed in the report.

Browse Through More Similar Reports By The Business Research Company:

Gastrointestinal Stromal Tumor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Gastroesophageal Reflux Disease (GERD) Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Autoimmune Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.